The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation (FUROSCOPE)

American University of Beirut Medical Center

Status and phase: Not yet enrolling; Phase 3

Conditions: Chronic Obstructive Pulmonary Disease Exacerbation; COPD Exacerbation

Treatments: Drug: Furosemide; Drug: Normal saline

Study type: Interventional

Funder types: Other

Identifiers

NCT05769738

BIO-2022-0187

Details and patient eligibility

About

The goal of this randomized controlled trial is to determine the effect of adding inhaled furosemide to the known treatment of patient with Chronic obstructive pulmonary disease (COPD) exacerbation. It primarily aims at studying its effect on:

1. Relief of dyspnea sensation
2. Length of hospital stay

Participants will be receiving the standard therapy of COPD exacerbation plus either inhaled furosemide or inhaled saline over 3 days. They will be asked to:

• Perform spirometry
• Fill in dyspnea score
• Do arterial blood gases (ABGs)

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years
• Diagnosed with COPD
• Presenting with COPD exacerbation
• Requiring hospitalization

Exclusion criteria

• Hemodynamically instability (systolic blood pressure ≤ 90mmHg, heart rate ≥ 120 or ≤ 50 Bpm)
• Decreased level of consciousness
• Non-invasive mechanical ventilation or intubation at the time of recruitment
• >5 liters of oxygen at the time of recruitment
• Pregnant patients
• Other primary pulmonary disease or heart failure exacerbation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

200 participants in 2 patient groups, including a placebo group

Furosemide group

Experimental group

Description:

Inhaled furosemide

Treatment:

Drug: Furosemide

Placebo group

Placebo Comparator group

Description:

Inhaled saline

Treatment:

Drug: Normal saline